All In Biotech

NDA 203752 · Noven

Minivelle

Estradiol · Transdermal · Estrogen

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Oct 29, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

49,932

22,740 serious, 915 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen-only therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in menopausal women with abnormal genital bleeding of unknown etiology [see Warnings and Precautions ( 5.2 )] . WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS See full prescribing information for complete boxed warning. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 )

What it is approved for

From the label in effect Nov 10, 2026.

MINIVELLE is indicated for: MINIVELLE ® is an estrogen indicated for: Treatment of moderate to severe vasomotor symptoms due to menopause ( 1.1 ) Prevention of postmenopausal osteoporosis ( 1.2 ) ​Limitations of Use When prescribing solely for the treatment of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 23, 2014 Supplement 4 · Efficacy LabelLetter
  • Oct 29, 2012 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
5 products under this application
  • MINIVELLE · ESTRADIOL 0.1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
  • MINIVELLE · ESTRADIOL 0.075MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
  • MINIVELLE · ESTRADIOL 0.025MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
  • MINIVELLE · ESTRADIOL 0.05MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
  • MINIVELLE · ESTRADIOL 0.0375MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,228
  • headache3,036
  • nausea2,980
  • fatigue2,930
  • off label use2,894
  • pain2,116
  • diarrhoea1,990
  • product adhesion issue1,969
  • dizziness1,780
  • hot flush1,710
  • breast cancer female1,709
  • arthralgia1,687

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004524
2005571
2006402
20071,461
2008428
2009598
2010952
2011840
20121,138
20131,364
20141,835
20152,392
20162,676
20172,464
20182,684
20193,016
20202,958
20212,883
20223,096
20233,581
20243,737
20255,300
20265,031

Recalls

10 FDA enforcement reports for this application.

  • Apr 16, 2021 · Class II · Terminated

    Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not...

  • Apr 16, 2021 · Class II · Terminated

    Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not...

  • Sep 7, 2018 · Class II · Terminated

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.

  • Sep 7, 2018 · Class II · Terminated

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.

  • Sep 7, 2018 · Class II · Terminated

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.

  • Sep 7, 2018 · Class II · Terminated

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.

  • May 4, 2018 · Class II · Terminated

    Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well...

  • May 4, 2018 · Class II · Terminated

    Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Minivelle (Estradiol)

2024 spending

$1.3M

Beneficiaries

660

2,918 claims

Per beneficiary

$1,934

$27.62 per unit

View as table
YearSpending
2020$1,921,982
2021$1,706,370
2022$1,505,764
2023$1,416,918
2024$1,276,110

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Noven

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.